Concise review

Fat and furious: Harnessing the full potential of adipose-derived stromal vascular fraction

Jordan A. Dykstra, Tiffany Facile, Ryan J. Patrick, Kevin Francis, Samuel Milanovich, Jill M. Weimer, Daniel J. Kota

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Due to their capacity to self-renew, proliferate and generate multi-lineage cells, adult-derived stem cells offer great potential for use in regenerative therapies to stop and/or reverse degenerative diseases such as diabetes, heart failure, Alzheimer’s disease and others. However, these subsets of cells can be isolated from different niches, each with differing potential for therapeutic applications. The stromal vascular fraction (SVF), a stem cell enriched and adipose-derived cell population, has garnered interest as a therapeutic in regenerative medicine due to its ability to secrete paracrine factors that accelerate endogenous repair, ease of accessibility and lack of identified major adverse effects. Thus, one can easily understand the rush to employ adipose-derived SVF to treat human disease. Perhaps faster than any other cell preparation, SVF is making its way to clinics worldwide, while critical preclinical research needed to establish SVF safety, efficacy and optimal, standardized clinical procedures are underway. Here, we will provide an overview of the current knowledge driving this phenomenon, its regulatory issues and existing studies, and propose potential unmapped applications.

Original languageEnglish (US)
Pages (from-to)1096-1108
Number of pages13
JournalStem Cells Translational Medicine
Volume6
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Blood Vessels
Fats
Adult Stem Cells
Aptitude
Regenerative Medicine
Stromal Cells
Alzheimer Disease
Stem Cells
Therapeutics
Heart Failure
Safety
Research
Population

Keywords

  • Adipose
  • Adult stem cells
  • Autologous stem cell transplantation
  • Cellular therapy
  • Clinical trials
  • Mesenchymal stem cells

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Concise review : Fat and furious: Harnessing the full potential of adipose-derived stromal vascular fraction. / Dykstra, Jordan A.; Facile, Tiffany; Patrick, Ryan J.; Francis, Kevin; Milanovich, Samuel; Weimer, Jill M.; Kota, Daniel J.

In: Stem Cells Translational Medicine, Vol. 6, No. 4, 01.04.2017, p. 1096-1108.

Research output: Contribution to journalReview article

Dykstra, Jordan A. ; Facile, Tiffany ; Patrick, Ryan J. ; Francis, Kevin ; Milanovich, Samuel ; Weimer, Jill M. ; Kota, Daniel J. / Concise review : Fat and furious: Harnessing the full potential of adipose-derived stromal vascular fraction. In: Stem Cells Translational Medicine. 2017 ; Vol. 6, No. 4. pp. 1096-1108.
@article{e183da455a5b4dc3add5a182c86347e2,
title = "Concise review: Fat and furious: Harnessing the full potential of adipose-derived stromal vascular fraction",
abstract = "Due to their capacity to self-renew, proliferate and generate multi-lineage cells, adult-derived stem cells offer great potential for use in regenerative therapies to stop and/or reverse degenerative diseases such as diabetes, heart failure, Alzheimer’s disease and others. However, these subsets of cells can be isolated from different niches, each with differing potential for therapeutic applications. The stromal vascular fraction (SVF), a stem cell enriched and adipose-derived cell population, has garnered interest as a therapeutic in regenerative medicine due to its ability to secrete paracrine factors that accelerate endogenous repair, ease of accessibility and lack of identified major adverse effects. Thus, one can easily understand the rush to employ adipose-derived SVF to treat human disease. Perhaps faster than any other cell preparation, SVF is making its way to clinics worldwide, while critical preclinical research needed to establish SVF safety, efficacy and optimal, standardized clinical procedures are underway. Here, we will provide an overview of the current knowledge driving this phenomenon, its regulatory issues and existing studies, and propose potential unmapped applications.",
keywords = "Adipose, Adult stem cells, Autologous stem cell transplantation, Cellular therapy, Clinical trials, Mesenchymal stem cells",
author = "Dykstra, {Jordan A.} and Tiffany Facile and Patrick, {Ryan J.} and Kevin Francis and Samuel Milanovich and Weimer, {Jill M.} and Kota, {Daniel J.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1002/sctm.16-0337",
language = "English (US)",
volume = "6",
pages = "1096--1108",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "4",

}

TY - JOUR

T1 - Concise review

T2 - Fat and furious: Harnessing the full potential of adipose-derived stromal vascular fraction

AU - Dykstra, Jordan A.

AU - Facile, Tiffany

AU - Patrick, Ryan J.

AU - Francis, Kevin

AU - Milanovich, Samuel

AU - Weimer, Jill M.

AU - Kota, Daniel J.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Due to their capacity to self-renew, proliferate and generate multi-lineage cells, adult-derived stem cells offer great potential for use in regenerative therapies to stop and/or reverse degenerative diseases such as diabetes, heart failure, Alzheimer’s disease and others. However, these subsets of cells can be isolated from different niches, each with differing potential for therapeutic applications. The stromal vascular fraction (SVF), a stem cell enriched and adipose-derived cell population, has garnered interest as a therapeutic in regenerative medicine due to its ability to secrete paracrine factors that accelerate endogenous repair, ease of accessibility and lack of identified major adverse effects. Thus, one can easily understand the rush to employ adipose-derived SVF to treat human disease. Perhaps faster than any other cell preparation, SVF is making its way to clinics worldwide, while critical preclinical research needed to establish SVF safety, efficacy and optimal, standardized clinical procedures are underway. Here, we will provide an overview of the current knowledge driving this phenomenon, its regulatory issues and existing studies, and propose potential unmapped applications.

AB - Due to their capacity to self-renew, proliferate and generate multi-lineage cells, adult-derived stem cells offer great potential for use in regenerative therapies to stop and/or reverse degenerative diseases such as diabetes, heart failure, Alzheimer’s disease and others. However, these subsets of cells can be isolated from different niches, each with differing potential for therapeutic applications. The stromal vascular fraction (SVF), a stem cell enriched and adipose-derived cell population, has garnered interest as a therapeutic in regenerative medicine due to its ability to secrete paracrine factors that accelerate endogenous repair, ease of accessibility and lack of identified major adverse effects. Thus, one can easily understand the rush to employ adipose-derived SVF to treat human disease. Perhaps faster than any other cell preparation, SVF is making its way to clinics worldwide, while critical preclinical research needed to establish SVF safety, efficacy and optimal, standardized clinical procedures are underway. Here, we will provide an overview of the current knowledge driving this phenomenon, its regulatory issues and existing studies, and propose potential unmapped applications.

KW - Adipose

KW - Adult stem cells

KW - Autologous stem cell transplantation

KW - Cellular therapy

KW - Clinical trials

KW - Mesenchymal stem cells

UR - http://www.scopus.com/inward/record.url?scp=85017532740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017532740&partnerID=8YFLogxK

U2 - 10.1002/sctm.16-0337

DO - 10.1002/sctm.16-0337

M3 - Review article

VL - 6

SP - 1096

EP - 1108

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 4

ER -